After presiding over stormy years, John McHutchison picks his 'strategic partner' to run Assembly Bio
Throughout the string of negative news coming out of Assembly Bio, CEO John McHutchison held on to the hope that his team of antiviral experts would deliver a functional cure for hepatitis B. Even as the biotech scrapped its lead drug, he pointed to the promise of next-generation programs — while expanding the scope of research to other viral targets.
But he’s now putting the big turnaround play in a lieutenant’s hands.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.